Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion

International Journal of Clinical Pharmacology and Therapeutics

Volumn 36, Issue 5, 1998, Pages 246-252

  Silies, H ^a   Blaschke, G ^b   Hohenlochter B ^a   Rossi, R ^a   Jurgens H ^a   Boos, J ^a,b  

^a Dept of Pediat Hematol and Oncol ^*  (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Ifosfamide; Metabolism; Pharmacokinetics; Schedule

Indexed keywords

ACROLEIN; ANTINEOPLASTIC AGENT; CHLOROACETALDEHYDE; DRUG METABOLITE; IFOSFAMIDE; ISOPHOSPHORAMIDE MUSTARD;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOTOXICITY; DRUG EXCRETION; DRUG URINE LEVEL; GAS CHROMATOGRAPHY; HUMAN; HYDROXYLATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC ACTIVATION; NEPHROTOXICITY; NEUROTOXICITY; SCHOOL CHILD; URINARY EXCRETION;

ACETALDEHYDE; ACROLEIN; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD; FEMALE; HUMANS; IFOSFAMIDE; INFUSIONS, INTRAVENOUS; KIDNEY; MALE; NEOPLASMS; PHOSPHORAMIDE MUSTARDS;

EID: 0031967963     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Alarcon RA 1968 Fluorometric determination of acrolein and related compounds with m-aminophenol. Anal Chem 40: 1704-1708
2. Antman KH, Ryan L, Elias A, Sherman D, Grier HE 1989 Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 7: 126-131
3. Boddy AV, Yule SM, Wyllie R, Price L, Pearson ADJ, Idle JR 1993 Pharmacokinetics and metabolism of ifosfamide administration as a continuous infusion in children. Cancer Res 53: 3758-3764
4. Boddy AV, Yule SM, Wyllie R, Price L, Pearson ADJ, Idle JR 1995 Comparison of continuous infusion and bolus administration of ifosfamid in children. Eur J Cancer 31A: 785-790
5. Boos J, Göring M, Küpker F, Jürgens H, Blaschke G 1993 In vitro studies on the formation of active and inactive metabolites of ifosfamide by different organ systems. Pharm Pharmacol Lett 3: 119-122
6. Boos J, Welslau U, Ritter J, Blaschke G, Schellong G 1991 Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children. Cancer Chemother Pharmacol 28: 455-460
7. Boos J, Welslau U, Ritter J, Blaschke G, Schellong G 1992 Ifosfamid and its "Side Chain Oxidized" metabolites - Urinary excretion under different pediatric treatment schedules. Klin Pädiatr 204: 299-305
8. Cerny T, Castiglione M, Brunner K, Küpfer A, Matinelli G, Lind M 1990 Ifosfamide by continuous infusion to prevent encephalopathy. Lancet 335: 175
9. Cerny T, Küpfer A 1992 The enigma of ifosfamide encephalopathy. Ann Oncol 3: 679-681
10. Chang TKH, Weber GF, Crespi CL, Waxman DJ 1993 Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53: 5629-5637
11. Connors TA, Cox PJ, Farmer PB, Foster AB, Jarman M 1973 Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem Pharmacol 23: 115-129
12. Gonzales FJ 1989 The molecular biology of cytochrome P450s. Pharmacol Rev 40: 243-288
13. Goren MP 1991 Determination of urinary 2-and 3-dechloroethylated metabolites of ifosfamide by high-performance liquid chromatography. J Chromatogr Biomed Appl 570: 351
14. Goren MP, Wright RK, Pratt CB, Pell FE 1986 Dechloroethylation of ifosfamide and neurotoxicity. Lancet II: 1219-1220
15. Hill DL, Russel Laster W, Kirk MC, El Dareer S, Struck RF 1973 Metabolism of iphosphamide (2-2-chloroethylamino-3-2chloroethyltetrahydro-2H-1,3-2-oxazaphorphorine -2-oxid)] and production of a toxic iphosphamide metabolite. Cancer Res 33: 1016-1022
16. Jürgens H, Treuner J, Winkler K, Göbel U 1989 Ifosfamide in pediatric malignancies. Semin Oncol 16 (Suppl 3): 46-50
17. Küpker F, Boos J, Blaschke G, Jürgens H 1993 Inhibitors of ifosfamide metabolism by human and rat liver microsomes. J Clin Pharmacol 33: 1008
18. Kurowski V, Wagner T 1993 Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2-and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 33: 36-42
19. Kurowsky V, Cerny T, Küpfer A, Wagner T 1991 Metabolism and pharmacokinetics of oral and intravenous ifosfamide. J Cancer Res Clin Oncol 117 (Suppl IV): 148-153
20. Lewis LD, Fitzgerald DL, Harper PG, Rogers HJ 1990 Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism. Br J Clin Pharmacol 30: 725-732
21. Lewis LD, Meanwell CA 1990 Ifosfamide pharmacokinetics and neurotoxicity. Lancet 335: 175-176
22. Lind J, Roberts HL, Thatcher N, Idle JR 1990 The effect of route of administration and fractionation of dose on the metabolism of ifosfamide. Cancer Chemother Pharmacol 26: 105-111
23. Martina R, Crasnier F, Chouini-Lalanne N, Gilard V, Niemeyer U, de Forni M, Malet-Martino MC 1992 A new approach to the study of ifosfamide metabolism by the analysis of human body fluids with 31P nuclear magnetic resonance spectroscopy. J Pharmacol Exp Ther 260: 1133
24. Misiura K, Okruszek A, Pankiewicz K, Stec WJ, Czownicki Z, Utracka B 1983 Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine. J Med Chem 26: 674
25. Mohrmann M, Pauli A, Walkenhorst H, Schönfeld B, Brandis M 1993 Effect of ifosfamide metabolites on sodium-dependent phosphate transport in a model of proximal tubular cells LLC-PK1 in culture. Renal Physiol Biochem 16: 285-289
26. Mohrmann M, Ansorge S, Schmich U, Schönfeld B, Brandis M 1994 Toxicity of ifosfamide, cyclophosphamide, and their metabolites in renal cell tubular cells in culture. Ped Nephrol 8: 157-163
27. Ninane J, Baurain R, Kraker J de, Ferster A, Trouet A, Cornu G 1989 Alkylating activity in serum, urine, and CSF following high-dose ifosfamide in children. Cancer Chemother Pharmacol 24 (Suppl): 82-86
28. Norpoth K, Addicks Hw, Witting U, Müller G, Raidt H 1975 Quantitative Bestimmung von Cyclophosphamid, Ifosfamid, und Trofosfamid sowie ihrer stabilen Metabolite auf der DC-Platte mit 4-Pyridinaldehyd-2-benzothiazolyhydrazon PHB. Arzneimittelforschung 25: 1331-1336
29. Rossi R, Gödde A, Kleinebrand A, Riepenhausen M, Boos J, Ritter J, Jürgens H 1994 Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol 12: 159-165
30. Rossi R, Horenkamp P, Pleyer J, Postler C, Boos J, Jürgens H 1995 The influence of short versus continuous ifosfamide infusion on the development of renal tubular impairment. Int J Ped Hematol Oncol (submitted)
31. Skinner R, Pearson ADJ, Price L, Coulthard MG, Craft AW 1990 Nephrotoxicity after ifosfamide. Arch Dis Child 65: 732-738
32. Skinner R, Sharkey IM, Pearson ADJ, Craft AW 1993 Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol 11: 173-190
33. Smeitink J, Verreussel M, Schröder C, Lippens R 1988 Nephrotoxicity associated with ifosfamide. Eur J Pediatr 148: 164-166
34. Wainer IW, Ducharme J, Granvil CP, Truedeau M, Leyland-Jones B 1994 Ifosfamide stereoselective dechloroethylation and neurotoxicity. Lancet 343: 982-3
35. Walker D, Flinois JP, Monkman SC, Beloc C, Boddy AV, Cholerton S, Daly AK, Lind MJ, Pearson ADJ, Beaune PH, Idle JR 1994 Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol 47: 1157-1163
36. Zamlauski-Tucker MJ, Morris ME, Springate JE 1994 Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney. Toxicol Appl Pharmacol 129: 170-175